Teen's death following Sarepta DMD gene therapy underscores a risk seen for decades [Yahoo! Finance]
Sarepta Therapeutics, Inc. (SRPT)
Last sarepta therapeutics, inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investorrelations.sarepta.com/events-and-presentations
Company Research
Source: Yahoo! Finance
The death this week of a teenager receiving Sarepta Therapeutics' gene therapy Elevidys for Duchenne muscular dystrophy is a tragic reminder of the stakes involved in cutting-edge biotech innovation. While gene therapies like Sarepta's offer an opportunity to treat and even cure diseases, that benefit carries risks. And although Elevidys has been used by more than 800 patients according to Sarepta , the recent death reflects concerns experts had with the therapy prior to its accelerated FDA approval in 2023 and full nod last year. Despite a failed late-stage trial, Sarepta pointed to the treatment's effect on secondary evidence of a functional mechanism of action. And Dr. Peter Marks, director of the FDA's Center for Biologics Evaluation and Research, ultimately overruled regulatory staff and a review team when he expanded the therapy's label to treat a wider range of patients. The 16-year-old boy whose death was reported this week suffered from acute liver failure. While liver
Show less
Read more
Impact Snapshot
Event Time:
SRPT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SRPT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SRPT alerts
High impacting Sarepta Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SRPT
News
- A mom was overjoyed when she learned a drug could save her baby's life. Then she learned it cost $2 million. [CBS News]CBS News
- Breakthrough genetic therapies can save lives, but many cost millions for single dose [CBS News]CBS News
- Sarepta Therapeutics Announces Refinancing of Approximately $291 Million of 1.25% Convertible Senior Notes due 2027Business Wire
- Sarepta Therapeutics (SRPT): Reassessing Valuation After a Sharp One-Month Share Price Rebound [Yahoo! Finance]Yahoo! Finance
- Sarepta Therapeutics (NASDAQ:SRPT) is now covered by analysts at Wedbush. They set an "outperform" rating and a $32.00 price target on the stock.MarketBeat
SRPT
Earnings
- 11/3/25 - Beat
SRPT
Sec Filings
- 12/18/25 - Form 4
- 12/16/25 - Form 144
- 12/11/25 - Form 8-K
- SRPT's page on the SEC website